Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "The Phase 2 KEYNOTE-B68 Trial - Efficacy & Safety of Pembro Every 6 Weeks in R/R cHL or Primary Mediastinal B-Cell Lymphoma"

161 views
June 14, 2023
Comments 0
Login to view comments. Click here to Login